Last reviewed · How we verify
NCT07478354: HIBR
Heart Institute BioRepository (HIBR) for Pediatric Heart Disease
trial in Cardiovascular Diseases (CVD) in 5,000 participants. Currently enrolling.
1 January 2050
Quick facts
| Lead sponsor | Children's Hospital Medical Center, Cincinnati |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 27 January 2012 |
| Primary completion | 1 January 2050 |
| Estimated completion | 1 January 2050 |
| Sites | 1 location across United States |
Conditions studied
- Cardiovascular Diseases (CVD) — all drugs for Cardiovascular Diseases (CVD) →
Sponsor
Children's Hospital Medical Center, Cincinnati
Who can join
Eligibility, any sex, with Cardiovascular Diseases (CVD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to redefine the Heart Institute BioRepository (HIBR) to facilitate Investigator-initiated and programmatic basic, translational, clinical and outcomes research. For the purposes of this protocol, "tissue" will refer to any gross specimen obtained from a patient, including but not limited to blood, cardiovascular tissue, urine, saliva, and other tissues and bodily fluids, including explanted non-human prosthetics or grafts. In this context, "tissue" is synonymous with "sample" or "specimen." A "BioRepository" functions to systematically collect, maintain and govern tissue specimens.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07478354
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases (CVD)
Currently open trials in the same condition.
- NCT07133516 — A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography · recruiting
- NCT07043166 — Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens · recruiting
- NCT07248371 — Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases · recruiting
- NCT07025590 — Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study) · NA · recruiting
- NCT06903559 — Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients · Phase 1, PHASE2 · recruiting
Other Children's Hospital Medical Center, Cincinnati trials
Trials by the same sponsor.
- NCT07430332 — GLP-1 RA for Stage 1 Type 1 Diabetes · Phase 2 · not yet recruiting
- NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
- NCT07265141 — An Automated Virtual Reality Intervention to Enhance Firearm Safety Counseling in Pediatrics · NA · not yet recruiting
- NCT07217444 — Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation · NA · recruiting
- NCT07195123 — Evaluation of the SMART IBD App in Pediatric IBD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07478354 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital Medical Center, Cincinnati
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07478354.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing